CSL (OTCMKTS:CSLLY) was upgraded by Macquarie from a “neutral” rating to an “outperform” rating in a research note issued on Tuesday, The Fly reports.
Several other equities analysts also recently weighed in on CSLLY. Citigroup raised shares of CSL from a “neutral” rating to a “buy” rating in a research note on Wednesday, March 10th. JPMorgan Chase & Co. downgraded shares of CSL from an “overweight” rating to a “neutral” rating in a research note on Wednesday, January 27th. Credit Suisse Group raised shares of CSL from a “neutral” rating to an “outperform” rating in a research note on Tuesday, March 23rd. The Goldman Sachs Group downgraded shares of CSL from a “buy” rating to a “neutral” rating in a research note on Thursday, February 18th. Finally, Zacks Investment Research downgraded shares of CSL from a “hold” rating to a “sell” rating in a research note on Tuesday, April 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. CSL has a consensus rating of “Hold” and an average target price of $119.00.
CSLLY traded up $0.81 during midday trading on Tuesday, hitting $105.17. 50,415 shares of the company traded hands, compared to its average volume of 56,835. The business has a 50 day simple moving average of $102.34 and a two-hundred day simple moving average of $106.41. The company has a current ratio of 3.01, a quick ratio of 1.37 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $95.73 billion, a price-to-earnings ratio of 45.53 and a beta of 0.59. CSL has a 52-week low of $91.04 and a 52-week high of $117.98.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Featured Story: What sectors are represented in the Hang Seng index?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.